Mahendrabhai Gulabdas Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mahendrabhai Gulabdas Patel, on behalf of the promoter, promoter group, and persons acting in concert (PAC) of Lincoln Pharmaceuticals Limited, has filed a mandatory annual disclosure with the stock exchanges. As on March 31, 2025, the promoter group held 99,69,930 equity shares (face value Rs. 10 each) of the company. The disclosure confirms that no encumbrance (pledge, lien, or similar charge) was created on these shares, directly or indirectly, during the financial year 2024-2025. This is a routine compliance filing under SEBI's takeover regulations, requiring promoters to declare annually whether they have encumbered their holdings.
This is a neutral-to-mildly positive filing for shareholders, as it confirms promoters have not pledged their shares during the year, indicating no signs of financial stress or leveraged exits by the promoter group. No direct impact on stock price is expected from this routine compliance disclosure.